Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.31 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | NPY1R | P25929 | 1/20 | 0.31 |
| ▸ | NPY2R | P49146 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.30 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.30 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18421834 | 0.88 | ALDH1A1 (0.33) | HCAR3ABL1CD274HPGDCYP1A2 | |
| SCHEMBL21854406 | 0.88 | CYP1A2 (0.33) | HCAR3ABL1CD274HPGDCYP1A2 | |
| SCHEMBL29259924 | 0.85 | CYP1A2 (0.31) | HCAR3ABL1HPGDCYP1A2 | |
| SCHEMBL29259455 | 0.84 | MEN1 (0.35) | HPGDCYP1A2ALDH1A1KMT2AMAPT | |
| SCHEMBL13375094 | 0.82 | ALDH1A1 (0.36) | HCAR3ABL1CD274HPGDALDH1A1 | |
| SCHEMBL20641237 | 0.81 | GAA (0.37) | ABL1HPGDCYP1A2ALDH1A1KMT2A | |
| SCHEMBL22207434 | 0.81 | CYP1A2 (0.35) | HCAR3ABL1CD274HPGDCYP1A2 | |
| SCHEMBL9912468 | 0.80 | CYP1A2 (0.35) | ABL1CD274HPGDCYP1A2ALDH1A1 | |
| SCHEMBL2804353 | 0.80 | HCAR3 (0.38) | HCAR3ABL1CD274ALDH1A1KMT2A | |
| SCHEMBL3576511 | 0.80 | ALDH1A1 (0.40) | HCAR3ABL1HPGDALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118684633-A | Androgen receptor modulators and methods of use thereof | 埃萨制药股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-113195441-B | Androgen receptor modulators and methods of use thereof | 埃萨制药股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-118063457-A | Pyridone compounds, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20220380325-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2022-12-01 | — | — | US | disclosed |
| CN-113195441-A | Androgen receptor modulators and methods of use thereof | 埃萨制药股份有限公司 | 2021-07-30 | — | — | CN | disclosed |
| US-11059795-B2 | Androgen receptor modulators and methods for their use | ESSA PHARMA, INC. (CA) | 2021-07-13 | — | — | US | disclosed |
| US-20200247763-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2020-08-06 | — | — | US | disclosed |
| WO-2020150545-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE WNT/B-CATENIN SIGNALING PATHWAY | SAMUMED, LLC (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200123117-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA, INC. (CA) | 2020-04-23 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20070105900-A1 | Pharmaceutical compounds | ATEX THERAPEUTICS, LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| US-20070105900-A1 | Pharmaceutical compounds | ATEX THERAPEUTICS, LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| US-20070105900-A1 | Pharmaceutical compounds | ATEX THERAPEUTICS, LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| EP-1648449-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| WO-2005002576-A2 | IMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | HCAR3 3093/4885ABL1 55/4885CD274 4429/4885 |
| US-20200247763-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, NR5A1, CYP17A1 | HCAR3 140/4885ABL1 2281/4885CD274 4226/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | HCAR3 3436/4885ABL1 63/4885CD274 3889/4885 |
| US-20200123117-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, NR5A1, CYP17A1 | HCAR3 140/4885ABL1 2281/4885CD274 4226/4885 |
| US-11059795-B2 | Androgen receptor modulators and methods for their use | AR, NR5A1, CYP17A1 | HCAR3 140/4885ABL1 2281/4885CD274 4226/4885 |
| US-20070105900-A1 | Pharmaceutical compounds | AURKA, AURKC, CDK1 | HCAR3 3470/4885ABL1 511/4885CD274 1156/4885 |
| US-20220380325-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, NR5A1, CYP17A1 | HCAR3 140/4885ABL1 2281/4885CD274 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.